InflaRx (IFRX) has released an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
InflaRx has received a positive opinion from the European Medicines Agency’s CHMP for GOHIBIC, a treatment targeting SARS-CoV-2-induced acute respiratory distress syndrome in adults. This recommendation, pending European Commission approval, highlights the drug’s potential to improve survival rates in critically ill COVID-19 patients. The development marks a significant milestone for InflaRx, boosting its stock appeal amidst ongoing challenges in COVID-19 treatment.
For further insights into IFRX stock, check out TipRanks’ Stock Analysis page.